title: Complement activation is critical for placental ischemia-induced hypertension in the rat.
abstract: Preeclampsia is a major obstetric problem defined by new-onset hypertension and proteinuria associated with compromised placental perfusion. Although activation of the complement system is increased in preeclampsia compared to normal pregnancy, it remains unclear whether excess complement activation is a cause or consequence of placental ischemia. Therefore, we hypothesized that complement activation is critical for placental ischemia-induced hypertension. We employed the reduced utero-placental perfusion pressure (RUPP) model of placental ischemia in the rat to induce hypertension in the third trimester and evaluated the effect of inhibiting complement activation with a soluble recombinant form of an endogenous complement regulator, human complement receptor 1 (sCR1; CDX-1135). On day 14 of a 21-day gestation, rats received either RUPP or Sham surgery and 15 mg/kg/day sCR1 or saline intravenously on days 14-18. Circulating complement component 3 decreased and complement activation product C3a increased in RUPP vs. Sham (p<0.05), indicating complement activation had occurred. Mean arterial pressure (MAP) measured on day 19 increased in RUPP vs. Sham rats (109.8±2.8 mmHg vs. 93.6±1.6 mmHg). Treatment with sCR1 significantly reduced elevated MAP in RUPP rats (98.4±3.6 mmHg, p<0.05) and reduced C3a production. Vascular endothelial growth factor (VEGF) decreased in RUPP compared to Sham rats, and the decrease in VEGF was not affected by sCR1 treatment. Thus, these studies have identified a mechanistic link between complement activation and the pregnancy complication of hypertension apart from free plasma VEGF and have identified complement inhibition as a potential treatment strategy for placental ischemia-induced hypertension in preeclampsia.
authors.affiliation: Department of Biomedical Sciences, University of Minnesota Medical School Duluth, Duluth, MN 55812, USA. lille067@umn.edu
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Lillegard
authors.forename: Alex C
authors.initials: AC
authors.lastname: Johnson
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Lojovich
authors.forename: Ashley J
authors.initials: AJ
authors.lastname: Bauer
authors.forename: Henry C
authors.initials: HC
authors.lastname: Marsh
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Gilbert
authors.forename: Jean F
authors.initials: JF
authors.lastname: Regal
mesh_terms: D000818:Animals; D062186:Arterial Pressure / Q000187:drug effects; D002339:Carotid Arteries / Q000187:drug effects / Q000503:physiopathology; D003167:Complement Activation / Q000187:drug effects / Q000502:physiology*; D003176:Complement C3 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000378:metabolism / Q000503:physiopathology*; D066298:In Vitro Techniques; D007511:Ischemia / Q000503:physiopathology*; D008297:Male; D009599:Nitroprusside / Q000494:pharmacology; D010920:Placenta / Q000098:blood supply / Q000378:metabolism / Q000503:physiopathology*; D011225:Pre-Eclampsia / Q000097:blood / Q000378:metabolism / Q000503:physiopathology; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D011951:Receptors, Complement / Q000008:administration & dosage; D013997:Time Factors; D014599:Uterus / Q000098:blood supply / Q000378:metabolism / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D003176:Complement C3; D011951:Receptors, Complement; D042461:Vascular Endothelial Growth Factor A; D014665:Vasodilator Agents; C082885:soluble complement inhibitor 1; D009599:Nitroprusside; D040281:Vascular Endothelial Growth Factor Receptor-1